On June 1, 2026, Harold Bernstein, who serves as President, R&D & CMO at Maze Therapeutics, Inc. (NASDAQ:MAZE), reported a significant sale of common stock valued at $381,112, according to recent filings with the Securities and Exchange Commission (SEC). These divestitures were structured under the terms of a pre-arranged Rule 10b5-1 trading plan.
The total sales involved two separate batches of shares. Initially, Bernstein disposed of 13,253 shares of Maze Therapeutics common stock. The weighted average price for this first batch was determined to be $25.5746 per share. These shares were sold through multiple transactions, with individual selling prices ranging between a low of $25.16 and a high of $26.10.
Following the initial sales, he executed another transaction involving 1,600 additional shares. For this second batch, the weighted average price reached $26.3576 per share. The individual prices recorded for these subsequent trades fluctuated between $26.16 and $26.53.
These insider sales are noted as MAZE shares were trading at $24.86 at the time of reporting, marking a recent decline of roughly 7% over the past week. Despite this temporary weakness in share price, the company has demonstrated robust performance historically, achieving a 78% return over the previous year for the firm, which carries a market capitalization of $1.34 billion.
From an analytical perspective, comprehensive insights provided by InvestingPro suggest that MAZE may currently appear slightly overvalued based on its current trading levels among over 1,400 US stocks analyzed by the platform.
Previous Activity and Current Holdings
Prior to these recent sales, Bernstein had engaged in a separate acquisition of shares. On the same day as the sales, he acquired 14,853 common stock shares through the exercise of stock options. These options were exercised at a cost of $10.42 per share, which represented a total value of $154,768.
The vested schedule for these options was contingent on his continued service to Maze Therapeutics, with portions vesting on October 3, 2023, and subsequent monthly anniversaries.
Following the combination of the recent selling activity and the earlier purchases, Harold Bernstein currently holds no shares of Maze Therapeutics common stock directly. However, he maintains an ongoing stake in the company through derivative securities, specifically holding 207,554 stock options.
Analyst Reaction to Clinical Development
In parallel with the reported insider transactions, Maze Therapeutics has drawn considerable attention due to the recent release of results from its Phase 2 HORIZON trial. This clinical investigation focused on evaluating MZE829, an APOL1 inhibitor, in patients suffering from APOL1-mediated chronic kidney disease.
The outcomes presented during this trial were characterized as promising. Consequently, multiple independent analysts have reiterated positive ratings for Maze Therapeutics, reflecting their confidence based on the company's recent scientific advancements. Several major financial institutions provided specific recommendations and price targets:
- BTIG maintained a Buy rating with an associated price target of $46.00.
- TD Cowen also reaffirmed a Buy rating, basing its assessment on the data generated by the trial.
- Raymond James expressed strong conviction in the stock, issuing a Strong Buy rating and setting a price target at $56.00, specifically highlighting the efficacy observed during the study.
- Truist Securities echoed this positive sentiment by maintaining a Buy rating and assigning a price target of $68.00, noting that the trial results were particularly significant for the FSGS subgroup.
- Additionally, Leerink Partners reiterated an Outperform rating while setting its price target at $50.00.
These collective developments underscore a positive reception from the analyst community concerning Maze Therapeutics' recent clinical trial outcomes and overall corporate progress.